Literature DB >> 6347371

Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain.

M I Bernhard, K A Foon, T N Oeltmann, M E Key, K M Hwang, G C Clarke, W L Christensen, L C Hoyer, M G Hanna, R K Oldham.   

Abstract

Monoclonal antibodies were raised against the guinea pig line 10 (L10) hepatocarcinoma, and an IgG1-producing hybridoma (D3) was selected for further study. D3 is a true monoclonal antibody as demonstrated by two-dimensional gel electrophoresis. Radioimmunoassays on live cells revealed no cross-reactivity with normal tissues or with the line 1 hepatocarcinoma which was used as a control. Membrane immunofluorescence assays demonstrated similar specificity. Immunoperoxidase staining of cryostat sections of tumor and normal tissues of both adult animals and fetuses showed that the D3 monoclonal antibody reacted primarily with the L10 tumor, but some cross-reactivity with smooth muscle, placenta, fetal skeletal muscle, and fetal liver was also demonstrated. Radioimmunoprecipitation of detergent extracts of iodinated L10 cells showed that the antigen is present on the cell surface as a dimer of Mr 290,000 (unit size, Mr 148,000). Therapy studies with unconjugated D3 antibody demonstrated a minor dose-dependent effect on tumor growth. D3 antibody conjugated to the A chain of diphtheria toxin (10(-7) M) was cytotoxic to 100% of L10 cells in vitro. Animals treated with a single 1-mg i.v. injection of this immunoconjugate on Day 7 following the intradermal injection of 10(5) tumor cells demonstrated a highly significant inhibition of tumor growth compared to control animals and those treated with unconjugated antibody.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347371

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  Photo-immunotargeting with haematoporphyrin conjugates activated by a low-power He-Ne laser.

Authors:  T Berki; P Németh
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

Authors:  F J Burrows; P E Thorpe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 4.  Immunotoxin therapy of malignant melanoma.

Authors:  L E Spitler
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

5.  Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.

Authors:  H Hara; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Monoclonal antibodies in the treatment of cancer: preliminary observations and future prospects.

Authors:  R K Oldham; A C Morgan; C S Woodhouse; R W Schroff; P G Abrams; K A Foon
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

8.  Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.

Authors:  D J FitzGerald; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 12.779

9.  Suppression of human alpha-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti alpha-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier.

Authors:  Y Tsukada; K Ohkawa; N Hibi
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.